m+Medelevator.RU
← Поиск публикаций
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025

Multi-omics characterization of cachexia-related genes reveals prognostic signatures and immune landscape in breast cancer.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Wang Siyu, Zhu Hongxia, Zhan Wendi, Hao Bo, Li Zhuo, Zhang Taolan

Аннотация

BACKGROUND: Cancer cachexia is a multifactorial syndrome affecting cancer prognosis and immune microenvironment. However, the roles of cachexia-related genes (CRGs) in breast cancer remain unclear.

METHODS: We performed differential expression analysis and weighted gene co-expression network analysis (WGCNA) on TCGA-BRCA data to identify key CRGs. A prognostic model was constructed using LASSO-Cox regression. Immune infiltration and treatment sensitivity were assessed, and single-cell RNA-seq analyses were conducted to explore gene function and cell-cell interactions.

RESULTS: A total of 82 CRGs were identified, and an 11-gene prognostic model was constructed, showing high predictive accuracy across multiple cohorts. Based on this model, we created a new risk score (Cachexia-related Risk Score for Breast Cancer, CRSBC) to categorize patients into high and low-risk groups. Low-risk patients had a better prognosis and good immune infiltration with higher sensitivity to immunotherapy. Single-cell analysis revealed HCCS as a key gene enriched in epithelial cells (breast cancer cells) and involved in macrophages recruitment via the MIF signaling pathway.

CONCLUSIONS: This study reveals the prognostic and immunological significance of CRGs in breast cancer and highlights HCCS as a potential therapeutic target.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты